# A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects

> **NCT04317885** · PHASE1 · COMPLETED · sponsor: **Shanghai Tongji Hospital, Tongji University School of Medicine** · enrollment: 25 (actual)

## Conditions studied

- Non-Hodgkin's B-cell Lymphoma

## Interventions

- **BIOLOGICAL:** Prizloncabtagene Autoleucel

## Key facts

- **NCT ID:** NCT04317885
- **Lead sponsor:** Shanghai Tongji Hospital, Tongji University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-05
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2025-05-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04317885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04317885, "A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04317885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*